Endoscopic bariatric and metabolic therapies (EBMTs) are a new category of therapies that expand the options for effective obesity treatment. These therapies require flexible endoscopy for either placement, removal, or procedure performance. EBMTs for primary obesity treatment can be divided into two categories: gastric therapies and small-bowel therapies.

Gastric EBMTs are placed or performed in the stomach, whereas small-bowel EBMTs are placed or performed in the small intestine. In general, gastric therapies result in weight loss, which is associated with improvements in metabolic outcomes, but do not have weight loss–independent effects on metabolic outcomes. Small-bowel therapies likely have both weight loss–dependent and weight loss–independent effects on metabolic outcomes, including blood glucose control.

Currently, the only EBMT devices or procedures that are approved for use by the U.S. Food and Drug Administration (FDA) are gastric therapies. These include intragastric balloons (IGBs), aspiration therapy, and a suturing device that has been approved for the general indication of tissue approximation in the gastrointestinal (GI) tract and is used for a procedure called endoscopic sleeve gastropasty (ESG). Multiple small-bowel therapies are being developed but are still in the research phase.

**FDA-Approved EBMTs**

**IGBs**

IGBs are space-occupying devices that are placed endoscopically or swallowed by patients. Although the IGBs currently available in the United States were approved in the past 2 years, they are not the first balloons to have received approval. The Garren-Edwards Gastric Bubble was the first IGB approved for use in the United States in 1985. Complications from this balloon, including gastric mucosa injury; deflation with migration into the small bowel, causing obstruction; and lack of weight loss (1–4) resulted in its removal from the market in 1988.

All of the currently approved IGBs were designed to address the issues that plagued the Garren-Edwards device (Table 1). Multicenter trials for FDA approval of both the ReShape and Obalon balloons were randomized, sham-controlled trials, whereas the multicenter trial for Orbera was an open-label randomized, controlled trial (RCT). All three trials demonstrated a significant percentage of total body weight loss (TBWL) compared...
to control conditions in intention-to-treat (ITT) analyses that included all subjects who underwent device or sham device placement (ReShape active 6.8% vs. control 3.3% TBWL; Obalon active 6.6 ± 5.1% vs. control 3.4 ± 5.0% TBWL; and Orbera active 10.2 ± 6.6% vs. control 3.3 ± 5.0% TBWL) (5–7). As expected, subjects in the open-label Orbera trial achieved higher weight loss than in the sham trials. Clinical case series from outside of the United States have demonstrated greater weight loss than in the U.S. RCTs (8,9). This discrepancy is likely multifactorial and may include increased patient baseline motivation to change, increased personalized lifestyle therapy, and patient self-payment, resulting in increased adherence to lifestyle changes. Clinical case series from the United States are not yet available, but it is possible that clinical experience within the United States will be similar to that from elsewhere. Moreover, in the U.S. multicenter trials, patients maintained 70–89.5% of their weight loss 6 months after balloon removal, and clinical case series demonstrate weight loss maintenance in up to 23% of patients at 5 years (10).

Cardiometabolic changes were evaluated in the U.S. pivotal trials of the ReShape, Orbera, and Obalon balloon systems. It is important to note that baseline metabolic parameters (i.e., fasting blood glucose, lipids, A1C, and blood pressure) were normal on average, and very few participants had a diagnosis of diabetes at study entry. Compared to subjects receiving the control condition of lifestyle therapy only, those treated with the Obalon balloon system had small but significant improvements in systolic blood pressure, fasting glucose, LDL cholesterol, and triglycerides at 24 weeks (11). Metabolic outcomes for the ReShape dual balloon were not reported compared to the control condition (12). No differences were seen between subjects in the control group and those treated with the Orbera balloon (13).

A clinic case series of 143 consecutive patients with a metabolic syndrome rate of 34.8% and a type 2 diabetes rate of 32.6% found a reduction in the incidence of metabolic syndrome to 14.5% and of diabetes to 20.9% at IGB removal, with 14.1 ± 5.7% TBWL (14). Moreover, 12 months after IGB removal, the TBWL remained high at 11.2 ± 4.6%, and incidence of metabolic syndrome and diabetes remained low at 11.6 and 21.3%, respectively (14).

Serious adverse events (AEs) were higher in the ReShape and Orbera trials than in the Obalon trial (10.6, 10, and 0.5%, respectively). Rates of serious AEs for both ReShape and Orbera were driven by dehydration requiring intravenous fluids due

---

**TABLE 1. FDA-Approved Intragastric Balloons**

| Images | Characteristics | FDA Status |
| --- | --- | --- |
| **ReShape dual balloon system** (ReShape Medical, San Clemente, Calif.) | • Two medical-grade silicone spheres joined by a flexible shaft • Each balloon is filled with 375–450 mL saline dyed with methylene blue • Endoscopically placed and removed | • Approved 28 July 2015 • For patients with a BMI of 30–40 kg/m² and one obesity-related comorbidity • Remains in place for 6 months |
| **Orbera intragastric balloon system** (Apollo Endosurgery, Austin, Tex.) | • Medical-grade silicone sphere • Filled with 400–700 mL saline • Endoscopically placed and removed | • Approved 5 August 2015 • For patients with a BMI of 30–40 kg/m² • Remains in place for 6 months |
| **Obalon balloon system** (Obalon Therapeutics, Carlsbad, Calif.) | • Thin polymer ellipse shape • Filled with 250 mL nitrogen mix gas • Three balloons administered in an 8- to 12-week period • Swallowed and endoscopically removed | • Approved 8 September 2016 • For patients with a BMI of 30–40 kg/m² • Remains in place for 6 months from first administration |
to nausea and vomiting after IGB placement or intolerability resulting in early device removal. The Obalon trial had only one serious AE due to a bleeding ulcer in a patient on protocol-prohibited nonsteroidal anti-inflammatory drugs. All serious AEs resolved without sequelae.

Nonserious AEs were common but varied slightly among the different IGBs. Vomiting was a more common AE in the ReShape and Orbera trials (86.7% and 86.8%, respectively) than in the Obalon trial (17.3%). Gastric ulceration occurred in 35% of ReShape subjects compared to 0 and 0.9% of Orbera and Obalon subjects, respectively; however, a design change during the ReShape trial reduced the ulceration rate to 10%. Incidence of gastroesophageal reflux disease was highest in the Obera trial, at 30% (5–7).

There are several management considerations for using IGB therapy for weight loss in patients with diabetes. First, IGBs are indicated for weight loss in patients with diabetes. Second, all patients initiating therapy with IGB and starting a low-calorie diet should have reductions in medications that can cause hypoglycemia. Moreover, the fluid-filled IGBs require a liquid and pureed diet for at least 2 weeks after IGB placement. Third, the fluid-filled IGBs can induce vomiting after placement, while a patient’s stomach is adjusting to accommodate the IGB. This can be managed with antiemetic medication, but it is important to adjust antidiabetic medications in anticipation of significant vomiting. Fourth, data suggest that the fluid-filled IGBs alter gut physiology, resulting in delayed gastric emptying that may correlate with weight loss (16), and baseline gastroparesis is considered a contraindication for IGB placement.

**Aspiration Therapy**

Aspiration therapy allows patients to remove a portion of their gastric contents after eating a meal with the use of the AspireAssist system (Aspire Bariatrics, King of Prussia, Pa.). The AspireAssist system contains both implanted components similar to a percutaneous endoscopic gastrostomy tube and components that are only used during aspiration (Figure 1). The implanted components include the A-tube, which is a silicone tube with a fenestrated 15-cm intragastric and extragastric portion separated by an intragastric bumper, and the skin-port, which is a <1-cm-high disc attached to the A-tube that can be opened to allow the flow of gastric contents. The components that are only used during aspiration include the connector, which attaches to and opens the skin-port and has a counter that locks and prevents further skin-port opening after 115 openings; the patient line, which connects the connector to the companion; the companion, which is a siphon with a one-way valve allowing for passive flow of gastric contents out or water flush into the stomach; the reservoir, which is a 600-mL soft water bottle filled with tap water used for flushing the system; and the drain tube, which is a silicone tube attached to the companion that directs the flow of gastric contents into the toilet or sink.

In addition to reducing the amount of food entering the small bowel, aspiration therapy also results in a decrease in food consumed at meals. This is caused by multiple factors, including the need to increase chewing to reduce food particle size to <5 mm to reliably fit through the A-tube, the requirement for increased water consumption during a meal, and an increased awareness of negative food choices due to the ability to see food contents exit through the clear drain tube. Analyses of the gastric aspirate in a U.S. pilot study revealed that only 80% of the weight loss was explained by aspiration of calories if the patient aspirated all meals and snacks optimally. Because subjects in that study only aspirated two meals on average and did not aspirate snacks, weight loss due to aspiration of gastric contents was likely significantly less than 80%, with reduced food intake responsible for significantly more than 20% of the weight loss (17).

Weight loss in trials for aspiration therapy have resulted in 14.2–19.8% TBWL in subjects with a BMI of 35–55 kg/m² who completed 12 months of therapy (17–19) and 21.4% TBWL in 11 subjects with a BMI of >55 kg/m² who completed 12 months of therapy (20). In the U.S. multicenter RCT (the PATHWAY study), the TBWL in the AspireAssist group was 12.1 ± 9.6% in the modified ITT analysis (n = 111) and 14.2 ± 9.8% in the completer analysis (n = 82) at 12 months compared to 3.5 ± 6.0% in the control group modified ITT analysis (n = 60) and 4.9 ± 7.0% in the control group completer analysis (n = 31) at 12 months (19). Two-year...
weight loss was reported in the U.S. pilot trial \((n = 7)\) and a Swedish single-arm prospective study \((n = 15)\), with 20.1 ± 3.5% TBWL and 61.5 ± 28.5% excess body weight loss (EBWL), respectively \((17,18)\).

As with the IGB trials, few subjects had abnormal cardiometabolic risk factors at baseline in the PATHWAY study, and only nine subjects had a diagnosis of diabetes. The study was not powered to detect changes in cardiometabolic risk factors; however, despite these limitations, A1C was decreased significantly more in the AspireAssist group than in the control group. Significant improvements were also seen in triglycerides and HDL cholesterol in the AspireAssist group compared to baseline \((19)\).

Five serious AEs occurred in four subjects in the PATHWAY study. One subject had severe abdominal pain after A-tube placement and required two separate overnight hospitalizations for pain control; one had mild peritonitis 2 days after A-tube placement requiring a 2-day hospitalization with intravenous antibiotics; one had gastric ulceration from the A-tube that was treated with removal of the A-tube; and one experienced a perforation of the stomach to create a tube shape along the lesser curve of the stomach \((21)\). Although the device does not have FDA approval, it does not have a specific indication for ESG, and no RCTs have been performed with this therapy. A study on mechanisms of action suggests that this procedure may cause a delay in gastric emptying that correlates with increased satiety; however, only four participants were studied \((22)\).

The largest case series of ESG was reported in 2017 and included 248 patients at three centers. TBWL 6 months after ESG was 15.2% (95% CI 14.2–16.25%), with 13% of patients lost to follow-up. Fifty-seven of the 92 patients who were eligible for the 24-month follow-up visit completed it, yielding a follow-up rate of 62%. TBWL in the patients who completed the 24-month visit was 18.6% (95% CI 13.7–21.5%) \((23)\).

Cardiometabolic outcomes were not reported in this case series but were reported in a case series of a subset of the patients \((n = 91)\) included in the original 248-case series. Follow-up at 12 months was conducted in 53 of the 91 patients with significant reductions in A1C, systolic blood pressure, fasting serum triglycerides, and serum alanine aminotransferase \((24)\).

Five serious AEs occurred in the 248-patient case series. These included two perigastric fluid collections requiring drainage and intravenous antibiotics, one case of extra-gastric bleeding requiring blood transfusion, one pulmonary embolism, and one pneumoperitoneum with pneumothorax requiring chest tube placement. It is important to note that the number of patients who required hospitalization for dehydration, nausea, or pain was not recorded. Nonserious AEs also were not recorded \((23)\).

The IOP has been used for the primary obesity surgery endoluminal (POSE) procedure. Case series of the POSE procedure in Europe in 147 patients \((BMI 38.0 ± 4.8 kg/m^2)\) demonstrated a TBWL of 15.1 ± 7.8% with 21% lost to follow-up at 12 months \((25)\). The POSE procedure was also studied in a multicenter, open-label RCT in Europe that demonstrated significantly more weight loss in the active group than in the control group \((TBWL of 13.0 ± 1.4% [SE] vs. 5.3 ± 2.5%, respectively, \(P = 0.01)\) \((26)\).

The POSE procedure was also studied in a U.S. multicenter, ran-
delayed gastric emptying and may not be appropriate for patients who have delayed gastric emptying from diabetic gastroparesis.

Investigational EBMTs
Two gastric EBMTs are currently being studied in U.S. multicenter RCTs, including one adjustable intragastric balloon (Spatz3 adjustable balloon system; Spatz FGIA, Great Neck, N.Y.) and the Transpyloric Shuttle (TPS; BAROnova, Inc., Goleta, Calif.). The Spatz3 system is a fluid-filled intragastric balloon with a catheter that allows for fill volume adjustment during an endoscopy after the initial placement. The TPS is a 56-mm outer silicone skin filled with a coiled cord of silicone tethered by silicone to a small weight. Unlike the intragastric balloons, this device causes intermittent gastric outlet obstruction by intermittently blocking the pylorus.

In addition, a U.S. multicenter RCT is being initiated on a completely procedureless intragastric balloon (Ellipse, Allurion Technologies, Natick, Mass.). This balloon is made of a thin film that is filled with 550 mL saline. It is swallowed by the patient and inflated after confirmation of the capsule in the stomach. The balloon has a release valve that catastrophically opens and deflates the balloon at 4 months. The balloon is then passed naturally through the GI tract.

Pilot studies of these devices have been performed outside of the United States, but whether these devices will become available in the United States will depend on the outcomes of the current trials.

Investigational Small-Bowel EBMTs
Multiple small-bowel EBMTs are being studied for the management of obesity and diabetes. These technologies were developed to mimic the effects on diabetes of proximal small-bowel exclusion seen with bariatric surgery.

Both animal and human data support the role of the proximal small bowel in glucose absorption, incretin secretion, and insulin resistance. Rat studies suggest that glucose sensing is decreased in the setting of diabetes (28), and high-fat feeding may stimulate duodenal proliferation of enteroendocrine cells that differentiate into K cells, producing glucose-dependent insulinotropic polypeptide (29). Moreover, proteins extracted from the duodenum and jejunum of diabetic mice and insulin-resistant humans caused insulin resistance in cultured muscle cells, suggesting that the duodenum and jejunum may also secrete a protein that causes skeletal muscle insulin resistance (30). Humans with diabetes have also been shown to have mucosal hypertrophy and increased enteroeudocrine cells in the proximal small bowel (31), and nutrient infusion into the jejunum with a feeding tube in patients with diabetes led to increases in the glucose absorption rate and insulin sensitivity (32).

Endoluminal Bypass Liners
The most well studied of these devices is the duodenal-jejunal bypass liner (EndoBarrier, GI Dynamics, Lexington, Mass.). This bypass liner is made from a 60-cm-long, ultra-thin film with a self-expanding nitinol ring with 10 barbs to anchor the device in the duodenal bulb. The ultra-thin film blocks nutrient interaction with the small-bowel mucosa until the film ends at 60 cm. A meta-analysis found a percentage of EBWL of 35.4% (95% CI 24.7–46.1%) at 12 months in three studies, with a decrease in A1C of –1.5% (95% CI –2.2 to –0.8) (9). However, the device had a pooled early removal rate of 18.4%, a migration rate of 4.9%, bleeding in 3.9%, and liver abscess in 0.13% (9). A U.S. multicenter, randomized, sham-controlled trial was stopped early after enrolling 325 of a planned 500 subjects because of a 3.5% incidence of hepatic abscess. All patients recovered after intravenous antibiot-
ics and percutaneous drainage (33). Despite the reduced number of subjects, the study still demonstrated a significant decrease in A1C in the active group compared to the sham control group (−1.0 and −0.3%, respectively). It is important to note that the average A1C of the study population was 8.8%, and they were already on oral antihyperglycemic agents (33). It is unclear why the rate of hepatic abscess was higher in this trial than in studies performed outside of the United States. The device is not available with the United States but is still available elsewhere.

Another endoluminal bypass liner, a gastro-duodeno-jejunal bypass liner (ValenTx, Maple Grove, Minn.), has been developed to bypass both the stomach and proximal small bowel. The device is a 120-cm-long fluoropolymer that is anchored to the gastroesophageal junction and deployed through the pylorus into the small bowel. Endoscopic placement initially required laparoscopic assistance (34) and was successfully performed in 22 subjects, with 17 subjects completing 12 weeks of implantation. Baseline BMI was 42 kg/m² (range 35.4–50.8 kg/m²), and weight loss was 16.8 kg (range 8.6–30.8 kg) (34). The study reported on seven subjects with diabetes on oral antihyperglycemic medications who did not need the medications at the end of the study, but no further detail was provided about this. An additional single-arm trial was performed with planned implantation duration of 12 months. Twelve patients underwent successful implantation, 10 completed 12 months of testing, and 6 patients had attached functional devices at 12 months (35). Weight loss was 14.9 kg at 12 months. Of four subjects with diabetes, three had a 1% decrease in A1C, and one stopped oral antihyperglycemic medications (35).

**Duodenal Mucosal Resurfacing**

Duodenal mucosal resurfacing (DMR) employs hydrothermal ablation to destroy the superficial mucosal layer and stimulate regrowth of normal mucosal tissue (Revita DMR system, Fractyl Laboratories, Lexington, Mass.). The device is a catheter capable of circumferential saline lift to protect the submucosa, followed by inflation of a 2-cm-long balloon filled with fluid heated to 90°C. Duodenal mucosa distal to the papilla and up to the ligament of Treitz are ablated under direct visualization in 2-cm increments. Similar principles are used in clinical practice for the ablation of Barrett’s esophagus mucosal tissue (36), with regrowth of normal squamous epithelium.

One human, open-label trial in 39 subjects (BMI 30.8 ± 3.5 kg/m², weight 84.4 ± 11.9 kg, and A1C 9.6 ± 1.4%) has been published (37). Subjects had 3–15 cm of ablation in the duodenum, with a decrease in A1C of 1.2 ± 0.3% at 6 months with only a 3% TBWL. In a subanalysis of subjects who had at least 9 cm of ablation and did not stop antihyperglycemic medications, the decrease in A1C was 1.8 ± 0.5% (37).

**Dual-Path Enteral Bypass**

The Incisionless Magnet Anastomotic System (GI Windows, Bridgewater, Mass.) is a new endoscopic therapy that requires the simultaneous deployment of self-assembling magnets in the proximal jejunum and ileum using pediatric colonoscopes under fluoroscopic guidance. The magnets attract each other and cause necrosis of the tissue compressed between the magnets, which leads to the creation of an anastomosis. The new dual-path enteral bypass allows for nutrients to flow through both the native and newly created anastomosis. The first human study was performed in 10 subjects (BMI 41 kg/m²), with data reported for 6-month outcomes. TBWL was 10.6%, and in four subjects who had diabetes (baseline A1C 7.8%), A1C decreased by 1.8%.

**Conclusion**

EBMTs are a new class of treatment for obesity and include gastric and small-bowel therapies. In contrast to gastric therapies, which have metabolic effects related to weight loss, small-bowel therapies have both weight loss–dependent and weight loss–independent effects on glucose homeostasis. Several gastric EBMTs are approved or available in the United States. The FDA-approved devices, including three intragastric balloons and aspiration therapy, have demonstrated safety and efficacy in RCTs. A large case series is available in support of the ESG procedure, which does not have specific FDA approval. Additional gastric and small-bowel devices and procedures are being studied for the treatment of obesity and diabetes and may become available in the United States soon. EBMTs offer needed options to improve obesity and diabetes treatment in the United States and abroad.

**Duality of Interest**

S.S. is a member of the American Gastroenterological Association Institute’s council section for Obesity, Metabolism, and Nutrition, an advisory board member for the Association for Bariatric Endoscopy, and vice president of The Obesity Society’s Bariatric Section. She is also currently a consultant for Obalon Therapeutics, Aspire Bariatrics, USGI Medical, and Spatz FGIA. In the past 12 months, she has performed contracted research through her institution for Aspire Bariatrics, Obalon Therapeutics, and Allurion Technologies. No other potential conflicts of interest relevant to this article were reported.

**References**

1. Benjamin SB. Small bowel obstruction and the Garren-Edwards gastric bubble: an iatrogenic bezoar. Gastrointest Endosc 1988;34:463–467.
2. Benjamin SB, Maher KA, Cattau EL Jr, et al. Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology 1988;95:581–588.
3. Kirby DF, Wade JB, Mills PR, et al. A prospective assessment of the Garren-Edwards Gastric Bubble and bariatric surgery in the treatment of morbid obesity. Am Surg 1990;56:575–580.
4. Zeman RK, Benjamin SB, Cunningham MB, et al. Small bowel obstruction due to Garren gastric bubble: radiographic diagnosis. AJR Am J Roentgenol 1988;150:581–582.
5. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED) ORBERA intragastric balloon.
system. Available from https://www.accessdata.fda.gov/cdrh_docs/pdf14/PI400008B.pdf. Accessed 22 September 2016
6. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED) ReShape integrated dual balloon system. Available from https://www.accessdata.fda.gov/cdrh_docs/pdf14/PI400012b.pdf. Accessed 22 September 2016
7. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED) Obalon balloon system. Available from https://www.accessdata.fda.gov/cdrh_docs/pdf16/PI60001b.pdf. Accessed 22 September 2016
8. Lopez-Nava G, Bautista-Castaño I, Jimenez-Baños A, Fernandez-Corbelle JP. Dual intragastric balloon: single ambulatory center Spanish experience with 60 patients in endoscopic weight loss management. Obes Surg 2015;25:2263–2267
9. Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015;82:425–438.e5
10. Kotzampani K, Gросоманидис V, Papakosta P, Penna S, ELEFTHERIADIS E. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg 2012;22:896–903
11. Sullivan S, Swan JM, Woodman G, et al. The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial [Abstract 812d]. Gastroenterology 2016;150(Suppl. 1):S1267
12. Ponce J, Woodman G, Swan J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015;11:874–881
13. Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes 2017;41:427–433
14. Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg 2009;19:1084–1088
15. ASGE Technical Committee; Abu Dayyeh BK, Thosani N, Konda V, et al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc 2015;81:502.e1–502.e16
16. Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring) 2016;24:1849–1853
17. Sullivan S, Stein R, Jonnalagadda S, Mullady D, Edmundowicz S. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013;145:1245–1252.e5
18. Norén E, Forssell H. Aspiration therapy for obesity: a safe and effective treatment. BMC Obes 2016;3:56
19. Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrosomotomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol 2017;112:447–457
20. Machtyka E, Turro R, Huberty V, et al. Aspiration therapy in super obese patients: pilot trial [Abstract No. 1944]. Gastroenterology 2016;150(Suppl. 1):S822–S823
21. Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc 2013;78:530–535
22. Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol 2017;15:37–43.e1
23. Lopez-Nava G, Sharaiah RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. Epub ahead of print on 27 April 2017 (DOI: 10.1007/s11695-017-2693-7)
24. Sharaiah RZ, Kumta NA, Saumoy M, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol 2017;15:504–510
25. López-Nava G, Bautista-Castaño I, Jimenez A, de Grado T, Fernandez-Corbelle JP. The primary obesity surgery endoluminal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015;11:861–865
26. Miller K, Turro R, Greve J, Bakker CM, Buchwald JN, Espinós JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after POSEM vs. medical therapy. Obes Surg 2017;27:310–322
27. Sullivan S, Swan JM, Woodman G, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring) 2017;25:294–301
28. Lee J, Cummings BP, Martin E, et al. Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2012;302:R657–R666
29. Gniuli D, Calcagnuolo A, Dalla Libera L, et al. High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia 2010;53:2233–2240
30. Salinari S, Dehard C, Bertuzzi A, et al. Ejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance. PLoS One 2013;8:e56258
31. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006;290:E550–E559
32. Salinari S, Carr RD, Guidone C, et al. Nutrient infusion bypassing duodenum-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects. Am J Physiol Endocrinol Metab 2013;305:E59–E66
33. Kaplan LM, Buse JB, Mullin C, et al. EndoBarrier therapy is associated with glycemic improvement, weight loss and safety issues in patients with obesity and type 2 diabetes on oral antihyperglycemic agents. Presented at the American Diabetes Association 76th Scientific Sessions, New Orleans, La., 2016
34. Sandler BJ, Rumbaut R, Paul Swan C, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 2011;25:3028–3033
35. Sandler BJ, Rumbaut R, Swan CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015;29:3298–3303
36. Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology 2016;151:822–835
37. Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 2016;39:2254–2261